AdAlta investor briefing – progress of AD-214 Phase I extension study

On 10 August 2023, AdAlta’s CEO and Managing Director, Dr Tim Oldham provided an update on lead drug AD-214, including the dosing of first participants in the Phase I extension study, recent data demonstrating potential efficacy of clinically convenient doses and partnering progress.

The AD-214 Phase 1 extension study will generate valuable data to inform and de-risk the design of the future AD-214 Phase II study, and progress partnering discussions.

During the webinar, Dr Oldham also discussed the unmet need for improved treatments for lung fibrosis patients for whom AD-214 is being developed. He highlighted Long Kayak for Lungs 2, the latest initiative by IPF survivor Bill Van Nierop to raise awareness of and funds for research into IPF, which AdAlta is supporting.

Click below to watch: